0001454789 false 0001454789 2023-03-27 2023-03-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 27, 2023

 

 

 

Astria Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37467   26-3687168
(State or other jurisdiction
of incorporation)		   (Commission File
Number)		   (IRS Employer
Identification No.)

 

75 State Street
Suite 1400		    
Boston, Massachusetts   02109
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (617) 349-1971

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange on which registered
Common Stock, $0.001 par value per share   ATXS   Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 27, 2023, Dr. Andrew Nichols notified Astria Therapeutics, Inc. (the “Company”) that he would resign from his position as Chief Scientific Officer of the Company, effective as of April 7, 2023.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
    Astria Therapeutics, INC.
     
Date: March 31, 2023 By: /s/ Ben Harshbarger
    Ben Harshbarger
    Chief Legal Officer

 

 

Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Catabasis Pharmaceuticals Charts.
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Catabasis Pharmaceuticals Charts.